Key Takeaways
- • Australian private equity firms executed at least 75 acquisitions of health care delivery assets between 2008–2022, totaling at least $24 billion, with acquisition activity accelerating from 3 deals in 2008 to 18 in 2022.
- • BGH Capital, a leading Australian private equity powerhouse, acquired ForHealth for $500 million in 2020 and subsequently secured contracts to operate approximately one-third of the government's urgent care clinics, positioning the firm to benefit from $8.5 billion in new Medicare incentives.
- • Genesis Capital acquired a majority stake in Ochre Health, a GP corporate operating more than 60 clinics across Australia, in a transaction demonstrating continued private equity appetite for primary care assets.
- • Australia-focused private equity funds with vintages between 2014–2021 delivered a median net IRR of 13.8%, outperforming other regions globally while maintaining one of the lowest risk profiles at 15.4% standard deviation.
- • Private equity's growing dominance in Australian health care mirrors global trends, with institutional investors increasingly deploying capital into primary care and health care delivery infrastructure as a defensible, recurring-revenue asset class.
Summary
Private equity investment in Australian health care delivery has reached substantial scale, with firms completing at least 75 acquisitions of health care delivery assets valued at a minimum of $24 billion between 2008 and 2022. The pace of acquisition activity has accelerated significantly, rising from just 3 identified deals in 2008 to 18 by 2022, signaling intensifying investor interest in the sector. This trend reflects a broader global shift, as private equity investors worldwide have become increasingly focused on health care delivery assets as sources of stable, recurring revenue with structural growth dynamics.
BGH Capital, one of Australia's most prominent private equity firms, exemplifies this strategic positioning. The firm acquired ForHealth, a medical centre network, for $500 million in 2020 and has substantially enhanced the asset's financial performance through successful government contracting. Notably, ForHealth won tenders to operate approximately one-third of the government's urgent care clinics across the country, including controlling half the footprint in Queensland, South Australia, and New South Wales. The asset is positioned to capture significant upside from the government's $8.5 billion in new Medicare incentives designed to reduce out-of-pocket fees for patients, effectively leveraging policy tailwinds to drive operational leverage and returns.
Genesis Capital, a specialist Australian health care investment firm, similarly demonstrated sector conviction by acquiring a majority stake in Ochre Health, a GP corporate with a footprint exceeding 60 clinics nationally. These transactions underscore the sector's appeal to sophisticated capital managers seeking exposure to fragmented primary care markets with consolidation upside.
From a portfolio construction perspective, Australian private equity has delivered competitive returns relative to global peers. Australia-focused private equity funds with vintages between 2014–2021 achieved a median net IRR of 13.8%, outperforming other regions while maintaining one of the lowest risk profiles globally, with a standard deviation of net IRR at 15.4%. As of September 2024, Australia-focused private capital commanded approximately $139 billion in assets under management, with private equity, venture capital, and private credit funds accounting for nearly half of total dry powder available for deployment at $39 billion.
The implications for health care delivery remain subject to ongoing scrutiny. International evidence from the United States demonstrates that private equity ownership can influence health care costs, care quality, workforce composition, and referral patterns. As private equity's footprint in Australian health care delivery expands materially, stakeholders—including medical practitioners, regulators, and policy makers—warrant heightened attention to the structural effects of financial engineering on patient outcomes and system efficiency.
BGH Capital, one of Australia's most prominent private equity firms, exemplifies this strategic positioning. The firm acquired ForHealth, a medical centre network, for $500 million in 2020 and has substantially enhanced the asset's financial performance through successful government contracting. Notably, ForHealth won tenders to operate approximately one-third of the government's urgent care clinics across the country, including controlling half the footprint in Queensland, South Australia, and New South Wales. The asset is positioned to capture significant upside from the government's $8.5 billion in new Medicare incentives designed to reduce out-of-pocket fees for patients, effectively leveraging policy tailwinds to drive operational leverage and returns.
Genesis Capital, a specialist Australian health care investment firm, similarly demonstrated sector conviction by acquiring a majority stake in Ochre Health, a GP corporate with a footprint exceeding 60 clinics nationally. These transactions underscore the sector's appeal to sophisticated capital managers seeking exposure to fragmented primary care markets with consolidation upside.
From a portfolio construction perspective, Australian private equity has delivered competitive returns relative to global peers. Australia-focused private equity funds with vintages between 2014–2021 achieved a median net IRR of 13.8%, outperforming other regions while maintaining one of the lowest risk profiles globally, with a standard deviation of net IRR at 15.4%. As of September 2024, Australia-focused private capital commanded approximately $139 billion in assets under management, with private equity, venture capital, and private credit funds accounting for nearly half of total dry powder available for deployment at $39 billion.
The implications for health care delivery remain subject to ongoing scrutiny. International evidence from the United States demonstrates that private equity ownership can influence health care costs, care quality, workforce composition, and referral patterns. As private equity's footprint in Australian health care delivery expands materially, stakeholders—including medical practitioners, regulators, and policy makers—warrant heightened attention to the structural effects of financial engineering on patient outcomes and system efficiency.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.